1. Osuga Y, Enya K, Kudou K, et al. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019;133:423–33.
2. Takeda. Uterine fibroids treatment agent (GnRH antagonists) “Rerumina for manufacturing and marketing approval in Japan of Tablets 40 mg” [media release]. 8 Jan 2019.
https://www.takeda.com/jp/newsroom/newsreleases/2019/20190108-8038/
.
3. Myovant Sciences. Relugolix Japanese prescribing information; 2019.
http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400256_2499013F1027_1_02
Accessed 7 March 2019.
4. Takeda, Roivant Sciences. Roivant Sciences and Takeda launch Myovant Sciences to develop innovative therapeutics for women’s health and prostate cancer [media release]. 6 June 2016.
http://www.takeda.com
.
5. Takeda, Aska Pharmaceutical. ASKA and Takeda enter into licensing agreement for Relugolix in women’s health indications [media release]. 31 May 2018.
http://www.takeda.com
.